Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal Disorders. Discover more about our strategic approaches.
The company is developing a range of pharmaceutical products that are based on new chemical entities and are targeted on skin diseases that can be topically treated.
Inflammatory Bowel Diseases (IBD) are a group of chronic, progressive, recurring and debilitating disorders characterized by severe damage of the gastro-intestinal tract.
Cosmo announces details of the successful phase III clinical trials of LuMeBlue™ which will be presented at its R&D day today
Cosmo announces details of the successful phase III clinical trial of Zemcolo in Travellers’ Diarrhoea, which will be presented at its R&D day today
Cosmo announces successful outcome of phase III clinical trial for LuMeBlue™
Read all news articles
Cosmo is a specialty pharmaceutical company that aims to become a global leader in the market of optimized therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for gastro-intestinal diseases.
Read more about us
Share price information
28/02/2017 - 01/03/2017
Credit-Suisse 2017 Global Health Care Conference in London
Get in touch with us today.
© 2017 Cosmo pharmaceuticals